Gabather – focus on CNS diseases

Diseases of the central nervous system (CNS) and mental health issues represent a major burden on society, and there is considerable room for improvements of the current therapeutic alternatives.

Swedish pharma company Gabather is working to alleviate this burden by developing therapies targeting the GABAA receptor, which is involved in a wide range of CNS […].